Skip to main content
Top
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

Melanoma with unknown primary: report and analysis of 24 patients

Authors: Rita Clerico, Ugo Bottoni, Giovanni Paolino, Marina Ambrifi, Paola Corsetti, Valeria Devirgiliis, Stefano Calvieri

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

In the literature, there are some papers reporting on patients with metastatic melanoma from an unknown primary lesion (MUP). The pathogenesis of this phenomenon and the prognosis of these patients are still debatable. Therefore, we reviewed our casistics on MUP patients. We identified 24 MUP patients out of all patients registered into a melanoma database from June 1996 to June 2011. The incidence was 1.4 %. We compared the survival rate of all patients with MUP stage III–IV with all patients with metastatic melanoma known primary (MMKP) stage III–IV observing a clear survival improvement for MUP patients in front of MMKP patients (p < 0.01). In a second instance, we compared stage III MUP patients with only lymph nodal involvement with stage III MMKP patients with only lymph nodal involvement, and again we found statistically significant better survival for MUP patients (p < 0.05). In this retrospective study, the number of lymph nodes involved (p = 0.8), the sex (p = 0.9), and S100 value (p = 0.2) were not statistically relevant for prognosis. The better prognosis for these patients is very similar to better survival rate for metastatic melanoma patients and vitiligo. This correlation may be in accord with the hypothesis of a regression of primary lesion by immunological system of the host and also the median age of patients at the time of diagnosis, commonly older than melanoma patients, may correspond to a long period of immunological interferences between the host and the melanoma disease.
Literature
1.
go back to reference Pack GT, Gerber DM, Scharnagel IM. End results in the treatment of malignant melanoma; a report of 1190 cases. Ann Surg. 1952;136:905–11.PubMedCrossRef Pack GT, Gerber DM, Scharnagel IM. End results in the treatment of malignant melanoma; a report of 1190 cases. Ann Surg. 1952;136:905–11.PubMedCrossRef
2.
go back to reference Das Gupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341–5. Das Gupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341–5.
3.
go back to reference Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Onc. 2009;27:6199–206.CrossRef Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Onc. 2009;27:6199–206.CrossRef
4.
go back to reference Jhaveri MB, Driscoll MS, Grant-Kels JM. Melanoma in pregnancy. Clin Obstet Gynecol. 2011;54:537–45.PubMedCrossRef Jhaveri MB, Driscoll MS, Grant-Kels JM. Melanoma in pregnancy. Clin Obstet Gynecol. 2011;54:537–45.PubMedCrossRef
5.
go back to reference Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35:507–13.PubMedCrossRef Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35:507–13.PubMedCrossRef
6.
go back to reference Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of uknown primary site. To make the long story short. A systematic review of the literature. Oncology Ematology. 2011;78:112–26. Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of uknown primary site. To make the long story short. A systematic review of the literature. Oncology Ematology. 2011;78:112–26.
7.
go back to reference Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National cancer data base. J Clin Oncol. 2007;25:1363–8.PubMedCrossRef Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National cancer data base. J Clin Oncol. 2007;25:1363–8.PubMedCrossRef
8.
go back to reference Wang BY, Lawson W, Robinson RA, Perez-Ordonez B, Brandwein M. Malignant Melanoma of the parotid: comparison of survival for patients with metastases from known vs unknown primary tumor sites. Arch Otolaryngol Head Neck Surg. 1999;125:635–9.PubMed Wang BY, Lawson W, Robinson RA, Perez-Ordonez B, Brandwein M. Malignant Melanoma of the parotid: comparison of survival for patients with metastases from known vs unknown primary tumor sites. Arch Otolaryngol Head Neck Surg. 1999;125:635–9.PubMed
9.
go back to reference Wilt DE, Farmer SE, Scolyer RA, Scolyer RA, McCaughan BC, Thompson JF. Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour ? Melanoma Res. 2005;15:531–7.PubMedCrossRef Wilt DE, Farmer SE, Scolyer RA, Scolyer RA, McCaughan BC, Thompson JF. Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour ? Melanoma Res. 2005;15:531–7.PubMedCrossRef
10.
go back to reference Savoia P, Fava P, Osella-Abate S, Nardò T, Comessatti A, Quaglino P, et al. Melanoma of unknown primary site: a 33-year experience at the turin melanoma centre. Melanoma Res. 2010;20:227–32.PubMed Savoia P, Fava P, Osella-Abate S, Nardò T, Comessatti A, Quaglino P, et al. Melanoma of unknown primary site: a 33-year experience at the turin melanoma centre. Melanoma Res. 2010;20:227–32.PubMed
11.
go back to reference McSwain B, Riddell DH, Richie RE, Crocker EF. Malignant melanoma report: report of 203 patients. Ann Surg. 1964;159:967–75.PubMedCrossRef McSwain B, Riddell DH, Richie RE, Crocker EF. Malignant melanoma report: report of 203 patients. Ann Surg. 1964;159:967–75.PubMedCrossRef
12.
go back to reference Einhorn LH, Burgess MA, Vallejos C, Bodey GP Sr, Gutterman J, Mavligit G, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 1974;34:1995–2004.PubMed Einhorn LH, Burgess MA, Vallejos C, Bodey GP Sr, Gutterman J, Mavligit G, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 1974;34:1995–2004.PubMed
13.
go back to reference Baab GH, McBride CM. Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg. 1975;110:896–900.PubMedCrossRef Baab GH, McBride CM. Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg. 1975;110:896–900.PubMedCrossRef
14.
go back to reference Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol. 1998;9:419–22.PubMedCrossRef Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol. 1998;9:419–22.PubMedCrossRef
15.
go back to reference Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg. 1977;64:805–8.PubMedCrossRef Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg. 1977;64:805–8.PubMedCrossRef
16.
go back to reference Lopez R, Holyoke ED, Moore RH. Malignant melanoma with unknown primary site. J Surg Oncol. 1982;19:151–4.PubMedCrossRef Lopez R, Holyoke ED, Moore RH. Malignant melanoma with unknown primary site. J Surg Oncol. 1982;19:151–4.PubMedCrossRef
17.
go back to reference Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg. 1981;191:98–104.CrossRef Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg. 1981;191:98–104.CrossRef
18.
19.
go back to reference Spiro RH, DeRose G, Strong EW. Cervical node metastasis of occult origin. Am J Surg. 1983;146:441–6.PubMedCrossRef Spiro RH, DeRose G, Strong EW. Cervical node metastasis of occult origin. Am J Surg. 1983;146:441–6.PubMedCrossRef
20.
go back to reference Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006;106:2012–20.PubMedCrossRef Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006;106:2012–20.PubMedCrossRef
21.
go back to reference Panagopoulos E, Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol. 1983;23:8–10.PubMedCrossRef Panagopoulos E, Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol. 1983;23:8–10.PubMedCrossRef
22.
go back to reference Klausner JM, Guzman M, Inbar M, Rozin RR. Unknown primary melanoma. J Surg Oncol. 1983;24:129–31.PubMedCrossRef Klausner JM, Guzman M, Inbar M, Rozin RR. Unknown primary melanoma. J Surg Oncol. 1983;24:129–31.PubMedCrossRef
23.
go back to reference Santini H, Byers RM, Wolf PF. Melanoma metastatic to cervical and parotid nodes from an unknown primary site. Am J Surg. 1985;150:510–2.PubMedCrossRef Santini H, Byers RM, Wolf PF. Melanoma metastatic to cervical and parotid nodes from an unknown primary site. Am J Surg. 1985;150:510–2.PubMedCrossRef
24.
go back to reference Muchmore JH, Krementz ET, Carter RD, Sutherland CM, Mendoza EA. Isolated perfusion of extremities for metastatic melanoma from an unknown primary lesion. South Med J. 1986;79:288–90.PubMedCrossRef Muchmore JH, Krementz ET, Carter RD, Sutherland CM, Mendoza EA. Isolated perfusion of extremities for metastatic melanoma from an unknown primary lesion. South Med J. 1986;79:288–90.PubMedCrossRef
25.
go back to reference Jonk A, Kroon BB, Rumke P, Mooi WJ, Hart AA, van Dongen JA. Lymph node metastasis from melanoma with an unknown primary site. Br J Surg. 1990;77:665–8.PubMedCrossRef Jonk A, Kroon BB, Rumke P, Mooi WJ, Hart AA, van Dongen JA. Lymph node metastasis from melanoma with an unknown primary site. Br J Surg. 1990;77:665–8.PubMedCrossRef
26.
go back to reference Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg. 1987;122:1380–3.PubMedCrossRef Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg. 1987;122:1380–3.PubMedCrossRef
27.
go back to reference Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991;214:627–36.PubMedCrossRef Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991;214:627–36.PubMedCrossRef
28.
go back to reference Norman J, Cruse CW, Wells KE, Saba HI, Reintgen DS. Metastatic melanoma with an unknown primary. Ann Plast Surg. 1992;28:81–4.PubMedCrossRef Norman J, Cruse CW, Wells KE, Saba HI, Reintgen DS. Metastatic melanoma with an unknown primary. Ann Plast Surg. 1992;28:81–4.PubMedCrossRef
29.
30.
go back to reference Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091–8.PubMedCrossRef Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091–8.PubMedCrossRef
31.
go back to reference Balm AJ, Kroon BB, Hilgers FJ, Jonk A, Mooi WJ. Lymph node metastases in the neck and parotid gland from an unknown primary melanoma. Clin Otolaryngol Allied Sci. 1994;19:161–5.PubMedCrossRef Balm AJ, Kroon BB, Hilgers FJ, Jonk A, Mooi WJ. Lymph node metastases in the neck and parotid gland from an unknown primary melanoma. Clin Otolaryngol Allied Sci. 1994;19:161–5.PubMedCrossRef
32.
go back to reference Nasri S, Namazie A, Dulguerov P, Mickel R. Malignant melanoma of cervical and parotid lymph nodes with an unknown primary site. Laryngoscope. 1994;104:1194–8.PubMed Nasri S, Namazie A, Dulguerov P, Mickel R. Malignant melanoma of cervical and parotid lymph nodes with an unknown primary site. Laryngoscope. 1994;104:1194–8.PubMed
33.
go back to reference Pappo AS, Kuttesch JF, Kaste SC, Parham DM, Rao BN, Pratt CB. Malignant melanocytic lesions of unknown primary site in children and adolescents. Med Pediatr Oncol. 1995;24:315–20.PubMedCrossRef Pappo AS, Kuttesch JF, Kaste SC, Parham DM, Rao BN, Pratt CB. Malignant melanocytic lesions of unknown primary site in children and adolescents. Med Pediatr Oncol. 1995;24:315–20.PubMedCrossRef
34.
go back to reference Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D 4th, et al. Melanoma of unknown primary site. Cancer. 1997;79:1816–21.PubMedCrossRef Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D 4th, et al. Melanoma of unknown primary site. Cancer. 1997;79:1816–21.PubMedCrossRef
35.
go back to reference Schlagenhauff B, StroebelW EllwangerU, Meier F, Zimmermann BreuningerH, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer. 1997;80:60–5.PubMedCrossRef Schlagenhauff B, StroebelW EllwangerU, Meier F, Zimmermann BreuningerH, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer. 1997;80:60–5.PubMedCrossRef
36.
go back to reference Sutherland CM, Chmiel JS, Bieligk S, Henson DE, Winchester DP. Patient characteristics, treatment, and outcome of unknown primary melanoma in the United States for the years 1981 and 1987. Am Surg. 1996;62:400–6.PubMed Sutherland CM, Chmiel JS, Bieligk S, Henson DE, Winchester DP. Patient characteristics, treatment, and outcome of unknown primary melanoma in the United States for the years 1981 and 1987. Am Surg. 1996;62:400–6.PubMed
37.
go back to reference Chang AE, Karnell LH, Menck HR. The National cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83:1664–78.PubMedCrossRef Chang AE, Karnell LH, Menck HR. The National cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83:1664–78.PubMedCrossRef
38.
go back to reference Conley J, Hamaker RC. Melanoma of the head and neck. Laryngoscope. 1977;87:460–4.PubMed Conley J, Hamaker RC. Melanoma of the head and neck. Laryngoscope. 1977;87:460–4.PubMed
39.
go back to reference Strobbe LJ, Jonk A, Hart AA, Nieweg OE, Kroon BB. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol. 1999;6:255–62.PubMedCrossRef Strobbe LJ, Jonk A, Hart AA, Nieweg OE, Kroon BB. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol. 1999;6:255–62.PubMedCrossRef
40.
go back to reference Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005;15:77–82.PubMedCrossRef Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005;15:77–82.PubMedCrossRef
41.
go back to reference Ravdel L, Robinson WA, Lewis K, Gonzalez R. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006;94:101–4.PubMedCrossRef Ravdel L, Robinson WA, Lewis K, Gonzalez R. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006;94:101–4.PubMedCrossRef
42.
go back to reference Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF. Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet. 1983;156:335–40.PubMed Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF. Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet. 1983;156:335–40.PubMed
43.
go back to reference Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26:535–41.PubMedCrossRef Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26:535–41.PubMedCrossRef
44.
go back to reference Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008;26:624–33.PubMedCrossRef Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008;26:624–33.PubMedCrossRef
45.
go back to reference Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009;27:3489–95.PubMedCrossRef Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009;27:3489–95.PubMedCrossRef
46.
47.
go back to reference Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pieñkowski A, Salamacha M, et al. Melanoma without detectable primary site with metastases to lymph nodes. Ann Surg Oncol. 2010;36:868–76. Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pieñkowski A, Salamacha M, et al. Melanoma without detectable primary site with metastases to lymph nodes. Ann Surg Oncol. 2010;36:868–76.
48.
go back to reference Gasparyan A, Amiri F, Safdieh J, Reid V, Cirincione E, Shah D. Malignant mucosal melanoma of the paranasal sinuses: Two case presentations. World J Clin Oncol. 2011;2:344–7.PubMedCrossRef Gasparyan A, Amiri F, Safdieh J, Reid V, Cirincione E, Shah D. Malignant mucosal melanoma of the paranasal sinuses: Two case presentations. World J Clin Oncol. 2011;2:344–7.PubMedCrossRef
49.
go back to reference Khademi B, Bahranifard H, Nasrollahi H, Mohammadianpanah M. Primary mucosal melanoma of the sinusal tract: report of 18 patients analysis of 1077 patients in the literature. Braz J Otorhinolaryngol. 2011;77:271.CrossRef Khademi B, Bahranifard H, Nasrollahi H, Mohammadianpanah M. Primary mucosal melanoma of the sinusal tract: report of 18 patients analysis of 1077 patients in the literature. Braz J Otorhinolaryngol. 2011;77:271.CrossRef
50.
go back to reference Sortino-Rachou AM, Cancela Mde C, Voti L, Curado MP. Primary oral melanoma: population-based incidence. Oral Oncol. 2009;45:254–8.PubMedCrossRef Sortino-Rachou AM, Cancela Mde C, Voti L, Curado MP. Primary oral melanoma: population-based incidence. Oral Oncol. 2009;45:254–8.PubMedCrossRef
51.
go back to reference Reddy BV, Sridhar GR, Anuradha CH, Chandrasekhar P, Lingamaneni KP. Malignant melanoma of the mandibular gingiva: a rare occurrence. Indian J Dent Res. 2010;21:302–5.PubMedCrossRef Reddy BV, Sridhar GR, Anuradha CH, Chandrasekhar P, Lingamaneni KP. Malignant melanoma of the mandibular gingiva: a rare occurrence. Indian J Dent Res. 2010;21:302–5.PubMedCrossRef
52.
go back to reference Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75–84.PubMedCrossRef Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75–84.PubMedCrossRef
53.
54.
go back to reference Nowecki ZI, Rutkowski P, Daiewirski W, Zdzienicki M, Pieñkowski G, Salamcha M, et al. Melanoma without detectable primary site with metastases to lymph nodes. Dermatol Surg. 2010;36:868–76.PubMedCrossRef Nowecki ZI, Rutkowski P, Daiewirski W, Zdzienicki M, Pieñkowski G, Salamcha M, et al. Melanoma without detectable primary site with metastases to lymph nodes. Dermatol Surg. 2010;36:868–76.PubMedCrossRef
55.
go back to reference Shenoy BV, Fort L III, Benjamin SP. Malignant melanoma primary in lymph node: the case of the missing link. Am J Surg Pathol. 1987;11:140–6.PubMedCrossRef Shenoy BV, Fort L III, Benjamin SP. Malignant melanoma primary in lymph node: the case of the missing link. Am J Surg Pathol. 1987;11:140–6.PubMedCrossRef
56.
go back to reference Ridolfi RL, Rosen PP, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer. 1977;39:164–71.PubMedCrossRef Ridolfi RL, Rosen PP, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer. 1977;39:164–71.PubMedCrossRef
57.
go back to reference Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedCrossRef Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedCrossRef
58.
go back to reference Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637–41.PubMedCrossRef Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637–41.PubMedCrossRef
59.
go back to reference Sun JY, Ning LS. Axillary skip metastases in breast cancer. Zhonghua Zhong Liu Za Zhi. 2008;30:352–5.PubMed Sun JY, Ning LS. Axillary skip metastases in breast cancer. Zhonghua Zhong Liu Za Zhi. 2008;30:352–5.PubMed
60.
go back to reference Rosen PP, Martin LL, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma analysis of 1228 Axillary Dissections. Ann Surg. 1983;197:276–83.PubMedCrossRef Rosen PP, Martin LL, Kinne DW, Beattie EJ. Discontinuous or skip metastases in breast carcinoma analysis of 1228 Axillary Dissections. Ann Surg. 1983;197:276–83.PubMedCrossRef
61.
go back to reference Kawano R, Hata E, Ikeda S, Yokota T. Lobe-specific skip nodal metastasis in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2008;14:9–14.PubMed Kawano R, Hata E, Ikeda S, Yokota T. Lobe-specific skip nodal metastasis in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2008;14:9–14.PubMed
62.
go back to reference Park SS, Ryu JS, Min BW, Kim WB, Kim SJ, Kim CS, et al. Impact of skip metastasis in gastric cancer. ANZ J Surg. 2005;75:645–9.PubMedCrossRef Park SS, Ryu JS, Min BW, Kim WB, Kim SJ, Kim CS, et al. Impact of skip metastasis in gastric cancer. ANZ J Surg. 2005;75:645–9.PubMedCrossRef
63.
go back to reference Prenzel KL, Bollschweiler E, Schröder W, Mönig SP, Drebber U, Vallboehmer D, et al. Prognostic relevance of skip metastases in esophageal cancer. Ann Thorac Surg. 2010;90:1662–7.PubMedCrossRef Prenzel KL, Bollschweiler E, Schröder W, Mönig SP, Drebber U, Vallboehmer D, et al. Prognostic relevance of skip metastases in esophageal cancer. Ann Thorac Surg. 2010;90:1662–7.PubMedCrossRef
64.
65.
go back to reference Prestwich RJ, Errington F, Llet EJ, Morgan RS, Scott KJ, Thompson J, et al. Tumor infection by oncolytic reoviruses adaptive antitumor immunity. Clin Cancer Res. 2008;14:7358–66.PubMedCrossRef Prestwich RJ, Errington F, Llet EJ, Morgan RS, Scott KJ, Thompson J, et al. Tumor infection by oncolytic reoviruses adaptive antitumor immunity. Clin Cancer Res. 2008;14:7358–66.PubMedCrossRef
66.
go back to reference Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 2008;15:1257–70.PubMedCrossRef Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 2008;15:1257–70.PubMedCrossRef
67.
go back to reference Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of type of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.PubMed Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of type of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.PubMed
68.
go back to reference Feldhahn M, Menzel M, Weide B, Bauer P, Meckbach D, Garbe C, et al. No evidence of viral genomes in whole-transcriptome sequencing of three melanoma metastases. Exp Dermatol. 2011;20:766–8.PubMedCrossRef Feldhahn M, Menzel M, Weide B, Bauer P, Meckbach D, Garbe C, et al. No evidence of viral genomes in whole-transcriptome sequencing of three melanoma metastases. Exp Dermatol. 2011;20:766–8.PubMedCrossRef
69.
go back to reference Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, et al. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 2003;63:8735–41.PubMed Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, et al. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 2003;63:8735–41.PubMed
70.
go back to reference Koburger I, Meckbach D, Metzler G, Fauser G, Garbe C, Bauer J. Absence of merkel cell polyoma virus in cutaneous melanoma. Exp Dermatol. 2011;20:78–9.PubMedCrossRef Koburger I, Meckbach D, Metzler G, Fauser G, Garbe C, Bauer J. Absence of merkel cell polyoma virus in cutaneous melanoma. Exp Dermatol. 2011;20:78–9.PubMedCrossRef
Metadata
Title
Melanoma with unknown primary: report and analysis of 24 patients
Authors
Rita Clerico
Ugo Bottoni
Giovanni Paolino
Marina Ambrifi
Paola Corsetti
Valeria Devirgiliis
Stefano Calvieri
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0217-9

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.